Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
Combination Weight Loss (CagriSema) Extensive Research The Phase 3 REDEFINE 1 trial demonstrated that CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) produced mean weight loss of 20.4% at 68 weeks in 3,417 adults with obesity or overweight without diabetes, compared to 14.9% with semaglutide alone, 11.5% with cagrilintide alone, and 3.0% with placebo
Promising treatments targeting the IFN- chemokine axis, JAK-STAT pathway, and Nrf2-ARE pathway, have recently emerged ( Figure 2 )
Body recomposition means reducing fat while preserving or improving lean muscle
CagriSema (the combination) was submitted for FDA approval in December 2025, but cagrilintide on its own is earlier in the process
Toxicology Findings Repeated-dose toxicity studies in rats, dogs, and mice for up to 6 weeks across doses from 6 mcg/kg to 20 mg/kg via various routes showed excellent tolerance
US$ 20.71
US$ 29.27
US$ 24.13
US$ 21.76
US$ 27.71
US$ 29.57
US$ 21.01
US$ 29.04
US$ 24.54
US$ 23.03
US$ 21.26
US$ 28.79
US$ 28.92